Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Download Data

Tela Bio Inc Invested Capital 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Tela Bio Inc Invested Capital 3 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Invested capital represents the total amount of capital invested in a company's operations, including both equity and debt. It is calculated by subtracting the sum of current liabilities (excluding short-term debt) from the total assets of a company. Invested capital reflects the long-term financial resources employed in the company's operations. It is an important measure to evaluate a company's capital structure and assess the amount of capital invested in its productive assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tela Bio Inc Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 204.95 M, a 372.05% change year over year.
Tela Bio Inc Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 43.42 M.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends